High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

PRIMARY OBJECTIVES: I. To estimate the immunogenicity of high-dose influenza vaccination in patients with central nervous system tumors. SECONDARY OBJECTIVES: I. To assess the geometric mean titer (GMT) in patients after administration of high-dose influenza vaccination compared to previously determined geometric mean titer (GMT) among 38 patients receiving the standard yearly influenza vaccination. II. To assess the seroconversion rates (i.e. four-fold rise in titer) compared to previously determined seroconversion following administration of the standard yearly influenza vaccination. III. To assess the seroprotection rates (i.e. post-vaccination titer \>= 1:40) compared to previously determined seroconversion and seroprotection following administration of the standard yearly influenza vaccination. TERTIARY OBJECTIVES: I. To assess the relationship between serologic markers of immune function and response to high-dose vaccination. OUTLINE: Patients receive trivalent influenza vaccine on day 1. After completion of study, patients are followed up at 28 days and/or 3 months.